Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals

Abd El Aziz, 2020, Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials, Diabetes, Obesity and Metabolism, 22, 699, 10.1111/dom.13924 Anz, 2014, The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses, Diabetes, Obesity and Metabolism, 16, 569, 10.1111/dom.12246 Appleton, 2001, Insulin Sensitivity decreases with obesity, and lean cats with low insulin sensitivity are at greatest risk of glucose intolerance with weight gain, Journal of Feline Medicine and Surgery, 3, 211, 10.1053/jfms.2001.0138 Baggio, 2002, Harnessing the therapeutic potential of glucagon-like peptide-1, Treatments in Endocrinology, 1, 117, 10.2165/00024677-200201020-00005 Baggio, 2007, Biology of incretins: GLP-1 and GIP, Gastroenterology, 132, 2131, 10.1053/j.gastro.2007.03.054 Baggio, 2017, The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice, Molecular Metabolism, 6, 1339, 10.1016/j.molmet.2017.08.010 Ban, 2008, Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways, Circulation, 117, 2340, 10.1161/CIRCULATIONAHA.107.739938 Beiroa, 2014, GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK, Diabetes, 63, 3346, 10.2337/db14-0302 Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor, Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 Bünemann, M., Gerhardstein, B.L., .Gao, T., & Hosey, M.M. (1999). Functional regulation of l-type calcium channels via protein kinase A-mediated phosphorylation of the β2 subunit. Journal of Biological Chemistry, 274(48), 33851–33854. 10.1074/jbc.274.48.33851. Buteau, 2004, Glucagon-like peptide-1 prevents beta cell glucolipotoxicity, Diabetologia, 47, 806, 10.1007/s00125-004-1379-6 Buteau, 2003, Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor, Diabetes, 52, 124, 10.2337/diabetes.52.1.124 Callegari-Jacques, S.M. (2003). Bioestatística: Princípios e aplicações. Porto Alegre: ARTMED. Camara, 2020, The daytime feeding frequency affects appetite-regulating hormones, amino acids, physical activity, and respiratory quotient, but not energy expenditure, in adult cats fed regimens for 21 days, PloS one, 15, 10.1371/journal.pone.0238522 Cao, 2019, GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials, Endocrine, 66, 157, 10.1007/s12020-019-02055-z Challa, 2012, Regulation of adipocyte formation by GLP-1/GLP-1R signaling, Journal of Biological Chemistry, 287, 6421, 10.1074/jbc.M111.310342 Chambers, 2017, The role of pancreatic preproglucagon in glucose homeostasis in mice, Cell Metabolism, 25, 927, 10.1016/j.cmet.2017.02.008 Chen, 2014, GLP-1 (7-36) amide restores myocardial insulin sensitivity and prevents the progression of heart failure in senescent beagles, Cardiovascular Diabetology, 13 Chia, 2020, Incretins in obesity and diabetes, Annals of the New York Academy of Sciences, 1461, 104, 10.1111/nyas.14211 Damholt, 1998, Glucagon-like-peptide-1 secretion from canine l-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose, Endocrinology, 139, 2085, 10.1210/endo.139.4.5921 Damholt, 1999, Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine, Cell and Tissue Research, 298, 287, 10.1007/s004419900093 Dardevet, 2005, Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors, American Journal of Physiology-Gastrointestinal and Liver Physiology, 289, 10.1152/ajpgi.00121.2005 de Heer, 2008, Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas, Diabetologia, 51, 2263, 10.1007/s00125-008-1149-y Deacon, 2018, Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes, Peptides, 100, 150, 10.1016/j.peptides.2017.10.011 Deacon, 2002, Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs, Journal of Endocrinology, 172, 355, 10.1677/joe.0.1720355 Delgado, 1995, Glucagon-like peptide-1 binding to rat skeletal muscle, Peptides, 16, 225, 10.1016/0196-9781(94)00175-8 DeVries, 2017, DPP-4 inhibitor–related pancreatitis: rare but real!, Diabetes care, 40, 161, 10.2337/dci16-0035 Drucker, 1987, Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line, Proceedings of the National Academy of Sciences, 84, 3434, 10.1073/pnas.84.10.3434 Drucker, 2018, The ascending GLP-1 road from clinical safety to reduction of cardiovascular complications, Diabetes, 67, 1710, 10.2337/dbi18-0008 Edgerton, 2009, Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like peptide 1 infusion increases liver glucose uptake in the conscious dog, Diabetes, 58, 243, 10.2337/db08-0515 El Bekay, 2016, Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes, British Journal of Pharmacology, 173, 1820, 10.1111/bph.13481 Elahi, 2014, GLP-1(32–36)amide, a novel pentapeptide cleavage product of GLP-1, modulates whole body glucose metabolism in dogs, Peptides, 59, 20, 10.1016/j.peptides.2014.06.004 Freyse, 1999, Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic, Metabolism, 48, 134, 10.1016/S0026-0495(99)90023-9 Furrer, 2010, The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats, The Veterinary Journal, 183, 355, 10.1016/j.tvjl.2008.11.017 Gilor, 2011, The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats, Domestic Animal Endocrinology, 41, 42, 10.1016/j.domaniend.2011.03.001 Gilor, 2011, The incretin effect in cats: Comparison between oral glucose, lipids, and amino acids, Domestic Animal Endocrinology, 40, 205, 10.1016/j.domaniend.2011.01.002 Gilor, 2016, What's in a name? Classification of diabetes mellitus in veterinary medicine and why it matters, Journal of Veterinary Internal Medicine, 30, 927, 10.1111/jvim.14357 Gilor, 2016, New approaches to feline diabetes mellitus, Journal of Feline Medicine and Surgery, 18, 733, 10.1177/1098612X16660441 Hall, 2015, Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats, Domestic Animal Endocrinology, 51, 114, 10.1016/j.domaniend.2014.12.001 Handgraaf, 2018, 17-β Estradiol regulates proglucagon-derived peptide secretion in mouse and human α- and L cells, JCI Insight, 3 Hayes, 2008, Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation, Endocrinology, 149, 4059, 10.1210/en.2007-1743 Herman, 2018, Regulation of hypothalamo-pituitary-adrenocortical responses to stressors by the nucleus of the solitary tract/dorsal vagal complex, Cellular and Molecular Neurobiology, 38, 25, 10.1007/s10571-017-0543-8 Hoelmkjaer, 2016, A Placebo-controlled study on the effects of the glucagon-like peptide-1 mimetic, exenatide, on insulin secretion, body composition and adipokines in obese, client-owned cats, PloS one, 11, 10.1371/journal.pone.0154727 Hoenig, 2013, Cats differ from other species in their cytokine and antioxidant enzyme response when developing obesity, Obesity, 10.1002/oby.20306 Holz, 2004, Epac : A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell, Diabetes, 53, 5, 10.2337/diabetes.53.1.5 I˙meryüz, 1997, Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms, American Journal of Physiology-Gastrointestinal and Liver Physiology, 273, G920, 10.1152/ajpgi.1997.273.4.G920 Ihara, 2015, An interaction between glucagon-like peptide-1 and adenosine contributes to cardioprotection of a dipeptidyl peptidase 4 inhibitor from myocardial ischemia-reperfusion injury, American Journal of Physiology-Heart and Circulatory Physiology, 308, 10.1152/ajpheart.00835.2014 Ionut, 2005, Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones, Diabetologia, 48, 967, 10.1007/s00125-005-1709-3 Ionut, 2006, Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action, American Journal of Physiology-Endocrinology and Metabolism, 291, E779, 10.1152/ajpendo.00106.2005 Ionut, 2016, Exenatide treatment alone improves β-cell function in a canine model of pre-diabetes, PloS one, 11, 10.1371/journal.pone.0158703 Jain, 2015, Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor, Journal of Diabetes, 7, 708, 10.1111/1753-0407.12233 Jain, 2017, ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus, British Journal of Pharmacology, 174, 2346, 10.1111/bph.13842 Johnson, 2007, Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels, American Journal of Physiology-Endocrinology and Metabolism, 293, 10.1152/ajpendo.00275.2007 Johnson, 2008, Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization, American Journal of Physiology-Endocrinology and Metabolism, 294, E380, 10.1152/ajpendo.00642.2007 Kang, 2008, Role of the cAMP sensor Epac as a determinant of K ATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells, The Journal of Physiology, 586, 1307, 10.1113/jphysiol.2007.143818 Kapodistria, 2018, Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis, Journal of Cellular and Molecular Medicine, 22, 2970, 10.1111/jcmm.13259 Kim, 2016, Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo, European Journal of Pharmacology, 788, 54, 10.1016/j.ejphar.2016.06.016 Knudsen, 2019, The discovery and development of liraglutide and semaglutide, Frontiers in Endocrinology, 10, 10.3389/fendo.2019.00155 Kooijman, 2015, Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice, Diabetologia, 58, 2637, 10.1007/s00125-015-3727-0 Krämer, 2020, Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release, Journal of Veterinary Internal Medicine, 34, 2287, 10.1111/jvim.15915 Krieger, 2016, Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia, Diabetes, 65, 34, 10.2337/db15-0973 Li, 2003, Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis, Journal of Biological Chemistry, 278, 471, 10.1074/jbc.M209423200 Lubbs, 2010, Dietary macronutrients and feeding frequency affect fasting and postprandial concentrations of hormones involved in appetite regulation in adult dogs, Journal of Animal Science, 88, 3945, 10.2527/jas.2010-2938 MacDonald, 2003, Antagonism of rat β-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways, Journal of Biological Chemistry, 278, 52446, 10.1074/jbc.M307612200 Maske, 2017, Estradiol modulates the anorexic response to central glucagon-like peptide 1, Hormones and Behavior, 93, 109, 10.1016/j.yhbeh.2017.05.012 McCool, 2018, The effect of diet, adiposity, and weight loss on the secretion of incretin hormones in cats, Domestic Animal Endocrinology, 62, 67, 10.1016/j.domaniend.2017.10.004 McMillan, 2016, Circulating concentrations of glucagon-like peptide 1, glucose-dependent insulinotropic peptide, peptide YY, and insulin in client-owned lean, overweight, and diabetic cats, Domestic Animal Endocrinology, 54, 85, 10.1016/j.domaniend.2015.10.001 Meloni, 2013, GLP-1 receptor activated insulin secretion from pancreatic β-cells: Mechanism and glucose dependence, Diabetes, Obesity and Metabolism, 15, 15, 10.1111/j.1463-1326.2012.01663.x Model, 2021, Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats, Molecular and Cellular Endocrinology, 524, 10.1016/j.mce.2021.111158 Model, 2021, Liraglutide treatment counteracts alterations in adipose tissue metabolism induced by orchiectomy in rats, Life Sciences, 278, 10.1016/j.lfs.2021.119586 Monami, 2017, Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials, Diabetes, Obesity and Metabolism, 19, 1233, 10.1111/dom.12926 Moore, 2013, Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog, American Journal of Physiology-Endocrinology and Metabolism, 305, E1473, 10.1152/ajpendo.00354.2013 Mori, 2016, Effect of acarbose, sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats, Research in Veterinary Science, 106, 131, 10.1016/j.rvsc.2016.04.001 Müller, 2019, Glucagon-like peptide 1 (GLP-1), Molecular Metabolism, 30, 72, 10.1016/j.molmet.2019.09.010 Nakamura, 2019, Liraglutide suppresses atrial electrophysiological changes, Heart and Vessels, 34, 1389, 10.1007/s00380-018-01327-4 Nauck, 2005, Glucagon-like peptide 1 and its derivatives in the treatment of diabetes, Regulatory Peptides, 128, 135, 10.1016/j.regpep.2004.07.014 Nauck, 2018, Incretin hormones: Their role in health and disease, Diabetes, Obesity and Metabolism, 20, 5, 10.1111/dom.13129 Navarro, 2016, Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male, Cell Metabolism, 23, 837, 10.1016/j.cmet.2016.03.015 Nikolaidis, 2005, Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy, American Journal of Physiology-Heart and Circulatory Physiology, 289, 10.1152/ajpheart.00347.2005 Nishii, 2014, Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats, Domestic Animal Endocrinology, 49, 14, 10.1016/j.domaniend.2014.04.006 Nishizawa, 2003, Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs, American Journal of Physiology-Endocrinology and Metabolism, 284, E1027, 10.1152/ajpendo.00503.2002 Oda, 2014, Preliminary study characterizing the use of sitagliptin for glycemic control in healthy beagle dogs with normal gluco-homeostasis, Journal of Veterinary Medical Science, 76, 1383, 10.1292/jvms.13-0590 Oda, 2013, Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs, Research in Veterinary Science, 95, 381, 10.1016/j.rvsc.2013.04.003 Ohneda, 1991, The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas, The Tohoku Journal of Experimental Medicine, 165, 209, 10.1620/tjem.165.209 Ohnuma, 2008, Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function, Trends in Immunology, 29, 295, 10.1016/j.it.2008.02.010 Ørskov, 1988, Effect of truncated glucagon-like peptide-1 [Proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach, Endocrinology, 123, 2009, 10.1210/endo-123-4-2009 Pacheco, 2011, Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats, Journal of Hypertension, 29, 520, 10.1097/HJH.0b013e328341939d Padrutt, 2015, Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats, Research in Veterinary Science, 99, 23, 10.1016/j.rvsc.2014.12.001 Porsani, 2020, Prevalence of canine obesity in the city of São Paulo, Brazil, Scientific Reports, 10, 14082, 10.1038/s41598-020-70937-8 Pyke, 2014, GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody, Endocrinology, 155, 1280, 10.1210/en.2013-1934 Reimann, 2002, Glucose-sensing in glucagon-like peptide-1-secreting cells, Diabetes, 51, 2757, 10.2337/diabetes.51.9.2757 Richards, 2014, Identification and characterization of GLP-1 receptor–expressing cells using a new transgenic mouse model, Diabetes, 63, 1224, 10.2337/db13-1440 Riederer, 2016, Effect of the glucagon-like peptide-1 analogue exenatide extended release in cats with newly diagnosed diabetes mellitus, Journal of Veterinary Internal Medicine, 30, 92, 10.1111/jvim.13817 Rowlands, 2018, Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function, Frontiers in Endocrinology, 9, 1, 10.3389/fendo.2018.00672 Rudinsky, 2015, Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats, Domestic Animal Endocrinology, 51, 78, 10.1016/j.domaniend.2014.12.003 Rüttimann, 2009, Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms, Endocrinology, 150, 1174, 10.1210/en.2008-1221 Sandhu, 1999, Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs, Diabetes, 48, 1045, 10.2337/diabetes.48.5.1045 Schauf, 2018, Effect of feeding a high-carbohydrate or a high-fat diet on subsequent food intake and blood concentration of satiety-related hormones in dogs, Journal of Animal Physiology and Animal Nutrition, 102, e21, 10.1111/jpn.12696 Scheen, 2018, The safety of gliptins : Updated data in 2018, Expert Opinion on Drug Safety, 17, 387, 10.1080/14740338.2018.1444027 Schneider, 2020, A once-monthly GLP-1 receptor agonist for treatment of diabetic cats, Domestic Animal Endocrinology, 70, 10.1016/j.domaniend.2019.07.001 Scuderi, 2018, Safety and efficacy assessment of a GLP-1 mimetic: Insulin glargine combination for treatment of feline diabetes mellitus, Domestic Animal Endocrinology, 65, 80, 10.1016/j.domaniend.2018.04.003 Seyfert, 2012, Effects of a glucagon-like peptide-1 mimetic (exenatide) in healthy cats, International Journal of Applied Research in Veterinary Medicine, 10, 147 Shimoda, 2011, The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes, Diabetologia, 54, 1098, 10.1007/s00125-011-2069-9 Sirohi, 2016, Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors, Physiology & Behavior, 161, 140, 10.1016/j.physbeh.2016.04.013 Skelin, 2011, cAMP increases the sensitivity of exocytosis to Ca2+ primarily through protein kinase A in mouse pancreatic beta cells, Cell calcium, 49, 89, 10.1016/j.ceca.2010.12.005 Smith, 2014, The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs, Cell Metabolism, 19, 1050, 10.1016/j.cmet.2014.04.005 Smits, 2017, Pancreatic effects of liraglutide or sitagliptin in overweight patients with type 2 diabetes: A 12-week randomized, placebo-controlled trial, Diabetes care, 40, 301, 10.2337/dc16-0836 Sugiyama, 1994, Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption, Digestion, 55, 24, 10.1159/000201118 Tang-Christensen, 1996, Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 271 Tolhurst, 2009, Nutritional regulation of glucagon-like peptide-1 secretion, The Journal of Physiology, 587, 27, 10.1113/jphysiol.2008.164012 Tsunekawa, 2007, Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies, Journal of Endocrinology, 193, 65, 10.1677/JOE-06-0148 Van Citters, 2002, Elevated glucagon-like peptide-1-(7–36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding, The Journal of Clinical Endocrinology & Metabolism, 87, 5191, 10.1210/jc.2002-020002 Vangoitsenhoven, 2012, GLP1 and cancer: Friend or foe?, Endocrine-Related Cancer, 19, 10.1530/ERC-12-0111 Wang, 1995, Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells, Endocrinology, 136, 4910, 10.1210/endo.136.11.7588224 Wettergren, 1997, The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation, Gut, 40, 597, 10.1136/gut.40.5.597 Yeh, 2021, DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity, Life Sciences, 278, 10.1016/j.lfs.2021.119574